Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis
Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis
复制标题
DOI：
10.1016/j.jneuroim.2007.12.008
复制
发表时间：
2008-03-01
影响因子：
3.3
通讯作者：
Yamada, Masahito
中科院分区：
文献类型：
--
作者：
Furukawa, Yutaka;Yoshikawa, Hiroaki;Yamada, Masahito
为了阐明他克莫司治疗重症肌无力的长期疗效、安全性和细胞因子网络调节作用，我们回顾性审查了 86 例新诊断连续患者和 9 例类固醇依赖患者的病历，并培养外周血单核细胞 (PBMC) 进行细胞因子谱分析。使用他克莫司观察到类固醇减少效果，并且没有观察到严重的不良反应。培养研究显示，接受他克莫司治疗的患者的 PBMC 中 IL-12、IL-17、IFN-γ、GM-CSF、TNF-α 和 MIP-1β 降低，IL-10 升高，这表明 T 细胞和巨噬细胞受到抑制，1 型调节性 T 细胞增强。 (C) 2007 Elsevier B.V. 保留所有权利。
To clarify the long-term efficacy, safety and the cytokine network-modulating effects of tacrolimus in myasthenia gravis, medical records of 86 newly diagnosed consecutive patients and nine steroid-dependent patients were retrospectively reviewed, and peripheral blood mononuclear cells (PBMC) were cultured for the cytokine profile. Steroid reduction effects were observed by using tacrolimus, and no serious adverse effects were observed. The culture study showed reduced IL-12, IL-17, IFN-gamma, GM-CSF, TNF-alpha and MIP-1 beta, and elevated IL-10 in the PBMC from patients who received tacrolimus, which suggests inhibition of T cells and macropbages, and enhancement of type 1 regulatory T cells. (C) 2007 Elsevier B.V. All rights reserved.